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Chimeric antigen receptor (CAR) engineered T cell therapies individually prepared for
each patient with autologous T cells have recently changed clinical practice in the
management of B cell malignancies. Even though CARs used to redirect polyclonal
T cells to the tumor are not HLA restricted, CAR T cells are also characterized by
their endogenous T cell receptor (TCR) repertoire. Tumor-antigen targeted TCR-based T
cell therapies in clinical trials are thus far using “conventional” αβ-TCRs that recognize
antigens presented as peptides in the context of the major histocompatibility complex.
Thus, both CAR- and TCR-based adoptive T cell therapies (ACTs) are dictated by
compatibility of the highly polymorphic HLA molecules between donors and recipients
in order to avoid graft-versus-host disease and rejection. The development of third-
party healthy donor derived well-characterized off-the-shelf cell therapy products that are
readily available and broadly applicable is an intensive area of research. While genome
engineering provides the tools to generate “universal” donor cells that can be redirected
to cancers, we will focus our attention on third-party off-the-shelf strategies with T cells
that are characterized by unique natural features and do not require genome editing
for safe administration. Specifically, we will discuss the use of virus-specific T cells,
lipid-restricted (CD1) T cells, MR1-restricted T cells, and γδ-TCR T cells. CD1- and MR1-
restricted T cells are not HLA-restricted and have the potential to serve as a unique
source of universal TCR sequences to be broadly applicable in TCR-based ACT as their
targets are presented by the monomorphic CD1 or MR1 molecules on a wide variety of
tumor types. For each cell type, we will summarize the stage of preclinical and clinical
development and discuss opportunities and challenges to deliver off-the-shelf targeted
cellular therapies against cancer.
Keywords: allogeneic off-the-shelf T cells, virus-specific T cells, unconventional T cells, engineered, CD1, MR1,
GVHD, rejection
INTRODUCTION
Engineered T cell therapies using chimeric antigen receptors (CARs) against CD19+ B cell
malignancies have been commercialized and have changed clinical practice. Current commercial
products aremanufactured in a highly personalized way for each individual patient with autologous
peripheral blood αβ-TCR T cells (1, 2). Challenges with the use of autologous products include
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aspects related to previous chemotherapies or allogeneic
hematopoietic cell transplantation (HCT) that can impact on
the quantity and quality of the starting material, uncontrollable
interpatient variability, and (too) long waiting times for the
patients due to global manufacturing chains (3–5). Thus, the
development of readily available off-the-shelf allogeneic immune
effector cell (IEC) therapy products is an attractive alternative
approach. Cell banks can be generated in advance; donors
can be well-characterized according to the desired biological
parameters of the final product. Major challenges to allogenic
IEC therapies include the possibility of dual rejection: infused
cells may produce graft-versus-host disease (GVHD), or the host
immune system may reject the infused cells (4–6).
In this review, we will seek, evaluate and discuss challenges
and opportunities for T cell-based IEC therapies, using naturally
occurring “universal” donor T cells. These cells are either
characterized by the recognition of well-defined HLA-restricted
conventional αβ-TCR antigens, or are HLA-independent and
recognize lipids, metabolites or phosphoantigens presented in
the context of non-polymorphic receptors on target cells. By
definition, these “universal” donor T cells do not produce
GVHD, do not require genome editing for safe application as a
therapeutic product, and have the capacity to potentially target
a wide variety of cancers. We will focus our review on human
preclinical and clinical developments including αβ-TCR T cells
[virus specific T cells (VSTs), CD1-, and MR1-restricted T cells]
as well as γδ-TCR T cells. Finally, we also discuss the potential use
of universal TCRs that can be inserted as transgenes into IECs.
Engineering of these “universal” donor T cells aims to combine
and simultaneously exploit the endogenous natural properties of
the cells with engineered properties that enhance the anti-tumor
potential of the final product (e.g., recognition of tumor-derived
lipids or metabolites by endogenous TCR and cell surface antigen
by the introduced CAR).
NATURALLY OCCURRING “UNIVERSAL”
DONOR T CELLS AS PLATFORMS FOR
T CELL ENGINEERING
αβ-TCR T Cell Subsets
Conventional αβ-TCR T cells express HLA-restricted TCRs
composed of an α- and a β-chain and recognize peptides
presented by HLA molecules on the cell surface of target
cells. Selected in the thymus, these T cells constitute the
majority of the circulating T cells in the human body (7).
Under physiologic conditions αβ-TCR T cells are polyclonal
and express an extremely diverse TCR repertoire to cover a
wide range of potential target antigens. This TCR diversity is
reduced in memory T cell pools that form upon antigen specific
expansion and clearance of a pathogen. VSTs directed against
cytomegalovirus (CMV) for example are characterized by their
oligoclonality, with a limited number of high avidity TCRs
dominating the pool of memory VSTs that can re-expand upon
repeated viral challenge (8–10). Unconventional αβ-TCR T cells
are non-HLA-restricted and recognize non-peptide targets that
are presented in the context of non-polymorphic molecules. In
fact, several types of unconventional αβ-TCR T cells express
semi-invariant TCRs, such as, for example, invariant natural
killer T (iNKT) cells that recognize targets in the context of the
monomorphic antigen-presenting molecule CD1, or mucosal-
associated invariant T (MAIT) cells that recognize targets in
the context of MR1 (Figure 1). Several of these αβ-TCR T cell
subsets therefore harbor unique features that could potentially
qualify them as universal donor cells for adoptive T cell therapy
(ACT) (Table 1).
Virus-Specific T Cells (VSTs)
Adoptive transfer of VSTs to prevent or treat infections
and/or EBV-associated post-transplant lymphoproliferation
Viral reactivations and infections after allogeneic HCT remain
a major cause of morbidity and mortality (29). Current anti-
viral drugs are associated with dose-limiting end organ toxicities
or lack of efficacy due to primary or secondary resistance,
and only virus-specific immune reconstitution can resolve the
issue of recurrent infections. Thus, in patients that do not
concomitantly present with GVHD, adoptive transfer of VSTs is
a safe and efficient therapy to accelerate immune reconstitution.
The various approaches of VST manufacturing for adoptive
transfer as well as clinical trial results have recently been
reviewed (30–32). Allogeneic HCT donor derived VSTs have
shown significant clinical activity against Epstein-Barr Virus
(EBV), CMV, adenovirus, BK virus, and Human Herpes Virus 6.
Importantly, impressive anti-viral responses have been reported
across studies, and significant alloreactivity or GVHD has only
been described in a very limited number of patients. HCT
donor derived Epstein-Barr Virus specific T cells (EBVSTs) are
also active against post-transplant EBV+ lymphoproliferative
disorders in 65–85% of treated patients (11, 33, 34), and
their long-term persistence was demonstrated in gene marking
studies (11).
With the goal to facilitate rapid access to VSTs including for
patients with seronegative donors, allogeneic third-party VST
banks have been developed by several groups and institutions
(12, 30, 35–37) and have entered commercialization. Safety and
anti-viral activity of adoptively transferred allogeneic third-party
donor VSTs are excellent, and the overall response rate (ORR)
when treating viral infections can reach up to 92% (36, 38).When
targeting EBV+ lymphoproliferation, ORRs were 68% in HCT
and 54% in solid organ transplant (SOT) patients (12). Because
persistence is a key parameter for tumor targeted T cell therapies
but has not been summarized in the recent review articles on
VSTs, we selected clinical trials with information on persistence
on the infused third-party VSTs and summarized the results in
Table 2. Available information is quite scarce. Each group used
different tracking methods, no gene-marking was available to
easily detect the in vivo fate of the infused cells, and long-term
follow-up is mostly lacking. Available data suggests that third-
party VSTs do not engraft and persist as well as HLA-matched
HCT donor-derived VSTs. The variability between patients and
trials was broad. Gallot et al. for example were not able to
detect significant levels of cells derived from the infused VST
lines (41). But others found a correlation between detection
of anti-viral activity (12, 38, 39, 42) or VST line derived TCR
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FIGURE 1 | Representation of the different αβ-TCR subsets. Schematic representation summarizing the different αβ-TCR subsets, their development and restricting
elements. The color grading of the TCR represents its clonality, from light to dark green (monoclonal to polyclonal, respectively). TCR, T cell receptor; VST,
virus-specific T cell; MHC, major histocompatibility complex; MAIT, mucosal-associated invariant T cell; GEM, germline-encoded mycolyl lipid-reactive; dNKT, diverse
natural killer T cell; iNKT, invariant natural killer T cell.
sequences (37, 40) and viral clearance. The limited persistence
is most likely due to rejection of the infused third party VSTs
by the host immune system. Thus, in order to overcome this
problem, novel types of chimeric alloimmune defense receptors
(ADRs) have been developed. One strategy consists of a chimeric
receptor using the extracellular part of human β2-microglobulin
and signaling through CD3ζ and was shown to protect VSTs from
alloreactive T cells in vitro, but this approach cannot protect
from NK cell mediated rejection (43). More recently, a receptor
recognizing 4-1BB (CD137)—temporarily upregulated on both
activated T and NK cells—and signaling through CD3ζ was
developed. 4-1BBζ ADR-engineered T cells were protected from
T and NK cell mediated rejection in vitro and in vivo in a mouse
xenograft model, and CARs retained their antitumor function
when co-expressed with the 4-1BBζ ADR (44). Thus, ADRs
have the potential to further enhance the persistence, efficacy,
universality and safety of third-party engineered VSTs, and can
be co-engineered with CARs. In the post-transplant setting,
endogenous immune reconstitution also plays an important role
in the establishment of long-term viral control.
We still need to learn more about the contributions of infused
cells and endogenously reconstituted anti-viral immunity upon
third-party VST adoptive transfer when targeting viral infections
or EBV-associated malignancies. Systematic assessment of VST
persistence with standardized methods across clinical trials
would facilitate this understanding.
Engineered VSTs in clinical trials
VSTs have been clinically validated as a cellular therapy
platform to genetically redirect antigen specificity against tumor-
associated antigens (Table 3). With this approach, endogenous
anti-viral TCR specificities can be exploited for the in
vivo expansion and stimulation of the transgenic VSTs or
targeting of viral-associated malignancies. Indeed, autologous
CAR-engineered VSTs have been evaluated in clinical trials
targeting GD2 for neuroblastoma (45, 46), and allogeneic
HCT donor-derived CAR+ VSTs targeting CD19 in B-acute
lymphoblastic leukemia (47–49). Reactivation of CMV in
patients after allogeneic HCT and CD19 CAR+ CMVST
infusion for example led to significant in vivo re-expansion
of the infused cells and CD19 directed cytotoxic activity with
elimination of B cells (49). To assess whether vaccination could
be used to in vivo re-expand CAR+ VSTs, a clinical trial is
underway to assess autologous GD2-CAR+ Varizella Zoster





























TABLE 1 | Features of universal donor cells.

























VST ++ +++ ++ – – – 7 Anti-viral (11, 12)




dNKT +++ + +++ ++ ++ + 12 Immune suppressive (7, 17, 18)
CD1a-restricted +++ + +++ + ++ + 11 Unknown (19–21)
CD1b GEM + + ++ + ++ + 8 Unknown (22, 23)
CD1b
LDN5-like
+ + ++ + ++ + 8 Unknown (22, 23)
CD1b-restricted ++ + +++ + ++ + 10 Unknown (19–21)
CD1c-restricted +++ + +++ + ++ + 11 Unknown (19–21)
MAIT + + +++ +++ ++ + 11 Unknown
γδ-TCR T cells





– – + – 4 Anti-tumoral,
pro-inflammatory
(28)
Table summarizing the different features restricting the use of a T cell subset as universal donor cells. The amplitude of each restricting feature is depicted as none/extremely low (–), low (+), intermediate (++) and high (+ + +). The
addition of each (+) is reported in the “Universality score” column, which represents the universal potential of each T cell subset, with a lower score corresponding to higher universality.
*Upon introduction of a transgenic TCR.
TCR, T cell receptor; VST, virus-specific T cell; MAIT, mucosal-associated invariant T cell; GEM, germline-encoded mycolyl lipid-reactive; dNKT, diverse natural killer T cells; iNKT, invariant natural killer T cells; HLA, human leukocyte
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EBV EBV+ lymphoma 33 SOT 5 TCR spectratyping Up to 7 days post-infusion




EBV EBV+ lymphoma 2, HCT (cord blood) 2 CTLp by LD No durable engraftment, but
transient CTLp increase 7–10
days after infusion
(39)
CMV, AdV, EBV Infection and
EBV+ lymphoma
50 HCT, 9 with EBV+
lymphoma




Clones derived from the VST
line detectable in 4 responders
up to 12 weeks
(40)
EBV EBV+ lymphoma 6 HCT
3 SOT
2 non-transplant
8 STR on PBMCs Signal barely detectable in 3/8






38 HCT, 1 with EBV+
lymphoma
16 responders IFN-γ ELISPOT with
informative epitopes
(VST line, patient or
shared origin)
11/16 (69%) persistence up to
12 weeks, HLA match at 2 or
more alleles
Confirmed by STR in 1 case
(38)
CMV Infection 10 HCT 8 IFN-γ ELISPOT with
informative epitopes
5/8 activity of infused VST line,
8/8 activity against shared
epitopes between line and
patient
(42)




STR on ex vivo EBV
restimulated T cells
HCT:
1: CR, 100% VST line derived
(day 10)
1: SD, no VST line derived cells
detected
1: CR, 100% VST line derived
cells day 32
SOT:
1: no response, no persistence
1: durable PR, long-term
persistence of VST line derived
cells (24 months)




EBV, Epstein-Barr Virus; CMV, Cytomegalovirus; AdV, Adenovirus; BKV, BK Virus; HHV6, Human Herpes Virus 6; SOT, Solid organ transplant; TCR, T cell receptor; HCT, hematopoietic
cell transplant; CTLp, cytotoxic T lymphocyte precursors; LD, limiting dilution; STR, short tandem repeat; PBMCs, peripheral blood mononuclear cells; IFN, Interferon; ELISPOT,
enzyme-linked immunospot; CR, complete response; PR, partial response; SD, stable disease.
VST (VZVSTs) cell infusions in combination with vaccination
(NCT01953900). Preclinical investigations had shown that anti-
tumor function of GD2-CAR+ VZVSTs could be rescued in
vitro upon stimulation with VZV peptide-pulsed dendritic
cells (DC) (50). A clinical trial with gene-modified third-
party partially HLA-matched healthy donor-derived banked
CAR+ EBVSTs targeting CD30 in patients with EBV-associated
CD30+ lymphomas is in preparation at Baylor College of
Medicine (NCT04288726).
Engineering VSTs with a tumor-targeted transgenic TCR has
been more challenging than with CARs, as forced expression of a
transgenic TCR leads to downregulation of the endogenous TCRs
(51). Indeed, these findings were confirmed in TCR transgenic
VSTs, where reduction of antiviral activity was reported in
several preclinical studies (52–55) and in one clinical trial
(56). Interestingly, one report showed that TCR+ VSTs can
shift their antigenic predominance depending on the type of
antigenic exposure given to the cells (viral or tumor antigen)
(55). The oligoclonal features of VSTs minimize the risk of
cross-pairing between transgenic and endogenous TCR chains,
and thus the use of VSTs to express a transgenic TCR is
thought to reduce the risk of both off-target toxicities and
GVHD. In the only clinical trial reported to date, a Wilms
tumor antigen-1 (WT-1) specific TCR was expressed in single
epitope specific EBVSTs generated from the HLA-matched HCT
donor. The clinical responses in high-risk AML patients who
received allogeneic HCT followed by prophylactic WT-1 TCR+
EBVST infusions were impressive (56). Unfortunately, no viral
reactivation occurred in the cohort of 12 treated patients,
so the question whether the level of anti-viral specificity is
sufficient to mediate in vivo re-expansion of TCR+ VSTs upon
viral reactivation and to protect against viral disease remains
elusive. TCR transgenic third-party VSTs have not yet been
evaluated clinically.
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TABLE 3 | Overview of clinical development status.














VST 0.01–0.2% Antigen specific expansion,
IFNγ-capture, multimer
selection
Yes CAR and TCR Low In phase 1 and 2
clinical trials
(45–56)
iNKT 0.01–0.2% α-GalCer-induced expansion Yes CAR and TCR Low In phase 1 clinical
trials
(57–60)
dNKT 1% Not done No Not done High Not in clinical trial (61)
CD1a-restricted 0.1–10% In vitro expansion with
CD1-expressing cells
No Not done High Not in clinical trial (62)
CD1b GEM < 0.01% Tetramer No Not done Low Not in clinical trial (22, 23)
CD1b LDN5-like < 0.01% Tetramer No Not done Low Not in clinical trial (22, 23)
CD1b-restricted 0.1–10% Single cell sorting for the
generation of T cell clones
No Not done High Not in clinical trial (63)
CD1c-restricted 0.1–10% Single cell sorting for the
generation of T cell clones
No Not done High Not in clinical trial (63, 64)
MAIT 5–10% Tetramer No Not done Low Not in clinical trial (65–67)
γδ-TCR T cells
Vγ9Vδ2 1–5% Zoledronate-induced expansion Yes CAR and TCR None In phase 1 clinical
trials
(68–70)
Vδ1 0.1–1% Beads selection and cytokine
expansion
Yes CAR and TCR None Clinical trials
expected soon
(71, 72)
*Upon introduction of a transgenic TCR. TCR, T cell receptor; VST, virus-specific T cell; MAIT, mucosal-associated invariant T cells; GEM, germline-encoded mycolyl lipid-reactive; dNKT,
diverse natural killer T cells; iNKT, invariant natural killer T cells; HLA, human leukocyte antigen; GVHD, graft-versus-host disease; APC, antigen-presenting cell; CAR, chimeric antigen
receptor; GMP, Good Manufacturing Practice.
VSTs as platform for engineered ACT: how universal can
they be?
Third-party banked VSTs have been established as a safe and
efficient ACT to treat infections and EBV+ lymphoproliferation
after allogeneic HCT or SOT. The oligoclonal nature of VSTs
limits their capacity to induce GVHD in this patient population.
Despite the polymorphic nature of HLA, VST banks can be built
with a limited number of well-chosen and characterized donors
to cover a highly diverse patient population (42). Furthermore,
VSTs can efficiently be redirected to tumors with both CARs
and TCRs for clinical use. Drawbacks of third-party VSTs are
that (i) their use has so far been limited to HCT and SOT
patients, (ii) the in vivo re-stimulation through the endogenous
TCR depends on unpredictable endogenous viral reactivations
or scheduled vaccinations, and (iii) their long-term persistence
has not yet been conclusively assessed. The clinical development
of engineering strategies such as incorporation of ADRs may
overcome these limitations in the future andmake VSTs safer and
more universal.
CD1-Restricted T Cells
Background on CD1 molecules
The monomorphic CD1 family is constituted of five members,
four extracellular (CD1a-CD1d) and one intracellular molecule
(CD1e). CD1a, CD1b, and CD1c belong to the group 1 CD1,
while group 2 is solely constituted of CD1d (7, 19). Circulating
within the different secretory and endosomal compartments of
the cells, CD1 molecules present a large array of lipid antigens to
T cells (7, 73–75). So far, only a limited number of CD1-restricted
antigens are known, consisting of lipids shared by multiple
microorganisms and of self-lipids that accumulate during cellular
stress, for example in cancer (19, 20, 76). CD1d expression is
constitutive and present on all antigen-presenting cells (APCs),
while the expression of CD1a/b/c is inducible and limited to a
subset of APCs. For example, B cells express CD1c, Langerhans
cells express CD1a and CD1e, while myeloid cells can express all
five CD1 molecules (19, 20).
CD1d-Restricted T cells: their implication in tumor
immunity
CD1d-restricted T cells, also called NKT cells, are selected in
the thymus after recognition of CD1d molecules expressed by
CD4+CD8+ double positive thymocytes (13, 19, 77). CD1d-
restricted T cells are classified into two distinct groups based
on their ability to recognize α-galactosylceramide (α-GalCer), a
glycosphingolipid originally derived from marine sponge. Type
I NKT, or iNKT, express a semi-invariant TCR consisting of an
invariant TCRα chain (TRAV10-TRAJ18 in human) paired with a
limited number of TCRβ chains and recognize α-GalCer. Type II
NKT, or dNKT, express amore diverse polyclonal TCR repertoire,
and are unresponsive to α-GalCer [(7); Figure 1].
α-GalCer is produced by the gut flora and many mammalian
tissues and acts as a potent iNKT cell stimulator (14, 78–80).
Dysregulated lipid production in tumors is also a source of
antigenic lipids capable of stimulating iNKT cells [e.g., GD3 and
GM3 in melanoma (81, 82), or α-fucosylceramides in colorectal
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and pancreatic adenocarcinomas (83)]. Upon TCR engagement,
iNKTs rapidly secrete high levels of cytokines (e.g., IFNγ,
TNFα, IL4, IL13, and IL17) and lytic granules (granzymes and
perforin), and upregulate killing receptors such as Fas ligand and
TRAIL (17, 84). Thus, iNKTs are rapidly cytotoxic and strongly
modulate the tumor microenvironment by direct targeting of
CD1d+ tumors, tumor-associated macrophages and myeloid-
derived suppressor cells (15, 85). Modulation of the immune
response occurs by transactivating NK cells, licensing DCs and
activating γδ-TCR T cells (16, 19, 86). This crosstalk leads to
a strong activation of the endogenous adaptive immune system
(87). That iNKTs play an important role in anti-tumor immunity
is inferred from the facts that low frequency of iNKT cells in
patients with hematologic or head and neck cancers correlated
with poor prognosis (88–90), while higher iNKT cell infiltration
in colorectal cancer correlated with longer survival (91). After
allogeneic HCT, higher doses of iNKT cells contained in the
graft were associated with protection from acute GVHD (92),
and early donor-derived iNKT cell reconstitution post-transplant
correlated with reduced acute GVHD and lower non-relapse
mortality while maintaining graft-versus-leukemia effects (93).
dNKTs are less well characterized and thought to have a
more immune regulatory role (17, 18, 94). In multiple myeloma
for example, dNKTs have been involved in suppression of anti-
tumor immunity in an IL-13-dependent manner (94). Potential
immunotherapeutic applications for dNKT cells have been
reviewed elsewhere (61).
Ex vivo expanded iNKT cells in clinical trials
Due to their biology, iNKT cells are an attractive cell type
to investigate for cancer immunotherapy (Table 3). However,
establishing GMP compatible ex vivo expansion protocols for
iNKT cells has been a hurdle to broader development. To date,
results from two clinical trials assessing the safety of adoptively
transferred ex vivo expanded autologous iNKT cells in cancer
patients were reported (95, 96). In a lung cancer trial, autologous
iNKT cells from 6 patients were expanded in the presence of
α-GalCer and IL2, reaching 0.1–25% iNKT cells in the final
products. Infusions were safe but no significant clinical responses
were seen (96). In a melanoma trial, autologous iNKT cells were
sorted from PBMCs and expanded ex vivo for 6–8 weeks with
anti-CD3 and IL2. Purity post-expansion ranged from 13 to 87%.
The nine treated patients had only minimal or no evidence of
disease at time of infusion and were not lymphodepleted. A clear
correlation between iNKT cell infusions, immune parameters
and outcome could not be established (95).
Meanwhile, ex vivo expansion methods have been refined
and now allow genetic engineering of iNKT cells (57, 58).
Dual targeting by harnessing endogenous and engineered
properties of iNKT cells produced very promising pre-clinical
results in neuroblastoma with GD2-CAR iNKT cells also
incorporating transgenic IL15 (57, 59) and in lymphoma
with CD19-CAR iNKT cells expanded in media containing
IL21 (58, 60). Both approaches have started phase I clinical
evaluation at Baylor College of Medicine. Safety of autologous
GD2-CAR.IL15 engineered iNKT cells is evaluated in patients
with neuroblastoma (NCT03294954). Since iNKT cells are not
alloreactive and clinical studies suggest that iNKTs can suppress
GVHD (92, 93, 97), a clinical trial with third-party allogeneic
off-the-shelf iNKT cells genetically engineered to express a
CD19-CAR and IL15 is underway to assess safety, in vivo
expansion and persistence, and responses in patients with B-cell
malignancies (NCT03774654).
CD1d-Restricted T cells as platform for ACT
iNKT cells have the ability to kill CD1d+ tumor cells and immune
suppressive cells in the tumor microenvironment through direct
cytotoxicity, but also modulate the immune response of NK cells
and DCs through cytokine secretion, producing enhanced anti-
tumor responses of conventional endogenous T cells (16, 19, 86).
In addition to its anti-tumor activity, iNKT cells can protect
the patient from developing GVHD after allogeneic HCT, as
better iNKT cell recovery correlated with a reduced risk of
GVHD (92, 93, 97). With their lack of HLA-restriction, semi-
invariant TCR and protective potential against GVHD, iNKT
cells possess several unique features required for universal donor
cells (Table 1). Their in vivo persistence will need to be analyzed.
The field is currently moving toward evaluating the safe use
of iNKT cells from allogeneic third-party universal donors in
engineered ACT (NCT03774654).
CD1a/b/c-Restricted T cells and their implication in
tumor immunity
The current knowledge on T cells restricted to group 1 CD1 is
limited, and mostly results from studies performed in vitro on
human T cell clones (62). Recognizing diverse microbial and
self-lipid antigens, group 1 CD1-restricted T cells are relatively
abundant among circulating lymphocytes in healthy individuals
(63), and the majority has a polyclonal TCR repertoire (19–21).
Two subsets of CD1b-restricted T cells, the germline-encoded,
mycolyl lipid–reactive (GEM), and the LDN5-like T cells, which
recognize glucose monomycolate, a lipid antigen derived from
Mycobacterium tuberculosis, express an invariant TCR (TRAV1-
TRAJ9, and TRAV17-TRBV4-1, respectively) (22, 23).
Group 1 CD1-restricted T cells are thought to participate in
immune surveillance of hematologic malignancies. Analysis of a
limited number of patient samples revealed positivity for CD1c
in 51% and CD1b in 54% of AML patients (n = 33), 71% of
B-ALL samples expressed CD1c (n = 7), and 75% of pediatric
T-ALL samples expressed CD1a and CD1b (n= 8) (64). Methyl-
lysophosphatidic acid (mLPA) is a self-lipid antigen presented
in the context of CD1c on hematological malignancies (64). T
cell clones recognizing mLPA in the context of CD1c produced
higher levels of IFNγ when stimulated with malignant than with
normal hematopoietic cells. Intracellular accumulation of mLPA
in tumor cells is thought to increase CD1c-restricted presentation
of mLPA on the cell surface compared to normal cells (64), and
therefore leading to differential recognition of malignant cells
with mLPA-restricted T cell clones.
Group 1 CD1-Restricted T cells as platform for ACT
Despite expression of CD1c on APC, tumor-reactive T cells
differentially recognized CD1c-restricted mLPA presented by
tumor cells, suggesting that CD1c-restricted lipid antigens
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specifically accumulate in malignant cells but not normal
APCs (64). If CD1c-restricted T cells are made amenable to
genetic engineering, they could be an interesting population
to investigate for ACT. Similar prospects apply to CD1a- and
CD1b-restricted T cells, as both CD1a and CD1b expression
is restricted to APCs (19, 20). Due to their polyclonal TCR
repertoire, CAR engineering could be more straightforward than
TCR engineering due to potential cross-pairing of transgenic
and endogenous TCR chains and higher risk to produce off-
target toxicities.
CD1b-restricted invariant TCR T cells (GEM and LDN5-like
T cells) theoretically are top candidates as universal donor cells
for both CAR and TCR-based ACT (Table 1). However, their
frequency is extremely low in M. tuberculosis positive patients
[<0.01% of peripheral blood T cells (22)], and has not yet been
described in healthy donors.
MR1-Restricted T Cells
General definition
The MR1 molecule is an evolutionary conserved, monomorphic
protein (98, 99). Ubiquitously expressed, MR1 cell surface
expression is however modulated by antigen abundance. Under
physiological conditions, MR1 is almost undetectable at the
cell surface. Bound antigen is needed for its trafficking to the
cell surface, and cell surface expression is further enhanced by
exogenous antigen loading (19, 98, 100). Known to be involved
in the immunity against bacterial and yeast infections (101, 102),
MR1 presents small metabolites derived from the metabolic
pathways of vitamin B9 (folate) or B2 (riboflavin) (103). Only a
few antigens have been identified so far, but the list is growing,
and includes small cyclic molecules utilized as pharmacological
agents, such as the aspirin analog 3-FSA (3-formylsalicylic acid)
or the non-steroidal anti-inflammatory drug diclofenac, which
suggests that MR1 may be involved in drug hypersensitivity
(104, 105). Even if self-derived MR1-restricted antigens have not
been identified yet, several studies suggest that such antigens
exist (106). For several years, mucosal-associated invariant T cells
(MAIT) were the only known T cells with MR1 restriction. Now
there is growing evidence that MR1-restricted non-MAIT cells
exist (107–109), but much more needs to be learned.
MR1-Restricted MAIT cells
MAIT cells develop upon interaction with CD4+CD8+ double
positive cortical thymocytes, and continue to mature and expand
after leaving the thymus [(105, 110, 111); Figure 1]. In humans,
their numbers continuously increase during the first 25 years
of life, and then slowly decrease with age (112, 113). Their
expansion is thought to be dependent on stimulation with
microbial antigens, as germ-freemice do not have anyMAIT cells
in the periphery, despite positive selection in the thymus (106).
Originally identified in the gut, MAIT cells are characterized
by the expression of a semi-invariant TCR, constituted
of an invariant TCR Vα chain (Vα7.2-Jα3.3) paired with
a limited number of Vβ chains. While byproducts of the
microbial riboflavin biosynthesis, such as 5-OP-RU (5-[2-
oxopropylideneamino]-6-D-ribitylaminouracil), are known to
strongly activate MAIT cells, the folate biosynthesis pathway
generates molecules, such as 6-formyl-pterin, that exert
inhibitory effects on MAIT cells (103, 114). Although MAIT
cells constitute only 5% of the total T cell pool in humans, their
frequency can greatly vary in different organs (105). MAIT cells
are abundant in the liver, lung and gastro-intestinal tract, as
well as in the blood. In the liver, for example, 45% of resident T
cells are MAIT (115). In the periphery, MAIT cells constitute up
to 10% of the circulating T cells (112). Similar to conventional
T cells, MAIT activities can be modulated by the antigen
recognized, the cytokines present in the microenvironment
and the tissue to which they naturally home. In the colon,
for example, MAIT cells preferentially display a Th1-type of
cytokine secretion, and reside in the lamina propria and the
intraepithelial compartment of the mucosa, while in lung and
liver MAIT cells resemble tissue-resident memory T cells (116).
TCR engagement together with co-stimulation leads to rapid
MAIT cell activation, in a memory-like manner (117, 118).
Activated MAIT cells display both direct and indirect cytotoxic
functions, through the secretion of granzyme B, perforin, and a
large range of Th1 and Th17 type of cytokines (105). Together
with their ability to home to infected sites, MAIT cells constitute
an important player in anti-microbial defense.
MAIT cells in tumor immunity
MAIT cells are part of the tumor infiltrating lymphocyte
population in colorectal cancer (116, 119, 120), hepatocellular
carcinoma (121, 122), or kidney and brain tumors (123). In
some tumors, an inverse correlation between circulating and
tumor infiltrating MAIT cells was observed, but it is not
clear yet if tumor-infiltrating MAIT cells are pro- or anti-
tumorigenic. In brain and kidney tumors, for example, MAIT cell
infiltration was associated with higher levels of pro-inflammatory
cytokines (123). On the other hand, MAIT cell infiltration in
colorectal cancer and hepatocellular carcinoma was associated
with unfavorable clinical outcome. Failing to produce pro-
inflammatory cytokines such as IFNγ upon ex vivo stimulation,
these tumor-infiltrating MAIT cells were functionally impaired
(119, 124). One study even showed by transcriptome sequencing
analyses that MAIT cells infiltrating hepatocellular carcinoma
acquired a pro-tumorigenic phenotype (122). Surprisingly,
peripheral MAIT cells seem to be unaffected and retain their
ability to respond to bacterial antigens and even to tumor cells
(116, 120, 124).
In patients after allogeneic HCT, robust peripheral blood
MAIT cell reconstitution has been associated with a lower risk for
the development of subsequent severe acute GVHD (118, 125),
and activated MAIT cells suppressed proliferation of CD4+ T
cells in vitro. Correlations between gut microbiota composition,
the related riboflavin pathway, and MAIT reconstitution exist
(118, 126). Further investigations are necessary to decipher
the precise role of MAIT cells in human GVHD and whether
adoptively transferred ex vivo expanded MAIT cells could be
immune suppressive.
MAIT cells as platform for ACT
MAIT cells possess unique features that would make them
interesting candidates as universal donor cells for ACT (Table 1),
Frontiers in Immunology | www.frontiersin.org 8 November 2020 | Volume 11 | Article 583716
Perez et al. Naturally Occurring “Universal” T Cells
and methods for their isolation and ex vivo expansion are
being established (65–67). However, their precise role in anti-
tumor immunity remains to be defined in more detail. Some
of the burning questions include (i) if it is possible to
reprogram them in vitro to express a stable Th1 profile, (ii)
if adoptively transferred MAIT cells efficiently migrate to the
tumor site and retain their anti-tumor function, and (iii) if
they can be genetically engineered during ex vivo expansion.
We are convinced that these and more questions will be
answered soon, and MAIT cells will be investigated as universal
donor cells.
γδ-TCR T Cell Subsets
γδ-TCR T cells constitute 1–5% of total circulating T cells
(14, 127). Selected in the thymus, the rearrangement process
of γδ-TCR is highly complex and not fully understood yet.
Constituted of a far smaller number of gene segments than
αβ-TCRs, only 4–6 functional Vγ and 8 Vδ vs. 46 Vα and
48 Vβ chains, the potential of γδ-TCR diversity is however
thought to surpass the diversity of αβ-TCRs (127, 128). Vδ4-
Vδ7 gene segments rearrange with segments of the TCR α-
chain, and have alternative TRAV names. Vδ1-Vδ2 preferentially
rearrange with Dδ, Jδ, and Cδ to create TCR δ-chains, though
few reports showed that Vδ1 and Vδ3 could also rearrange
with segments of the TCRα locus, thus generating a δ/αβ-TCR
T cell (129–132).
Vδ usage pre-determines γδ-TCR T cells function and
localization: the majority of peripheral γδ-TCR T cells expresses
Vδ2, while tissue-resident γδ-TCR T cells favor Vδ1 and Vδ3
(127). In humans, the majority of γδ-TCR T cells consists of Vδ1
and Vδ2 T cells (129). Their ligands are not well-characterized.
The Vγ9Vδ2 T cell subset recognizes phosphorylated antigens,
presented by the butyrophilin (BTN) molecules. Vδ1 γδ-TCR
T cells can recognize antigens presented on CD1c, CD1d,
and MR1 molecules. Both Vδ1 and Vδ2 γδ-TCR T cells are
able to recognize stress-related molecules such as MIC A/B




The Vγ9Vδ2 T cell subset is relatively abundant in circulating
lymphocytes, and represents 1–5% of all T cells in healthy
individuals, and 50–95% of γδ-TCR T cells (127, 135,
136). This T cell subset expresses an invariant TCR that
recognizes phosphorylated isoprenoid metabolites, also called
phosphoantigens, derived from the mevalonate pathway. These
metabolites, such as the isopentenyl pyrophosphate (IPP), can
accumulate in transformed and infected cells because of their
dysregulated metabolism (127, 135, 137). IPP accumulates
when the activity of the IPP-metabolizing enzyme farnesyl-
diphosphate-synthase (FPPS) is blocked (135). The use of
aminobiphosphonates, such as zoledronate, inhibits FFPS, which
leads to an increase in intracellular level of IPP and the activation
of Vγ9Vδ2 T cells (135, 138–140).
IPPs are presented to T cells by butyrophilin molecules.
Belonging to the immunoglobulin superfamily, these
glycoproteins are divided into three subfamilies (BTN1, BTN2,
BTN3) (141). Only BTN3A (CD277) presents phosphoantigens
to Vγ9Vδ2 T cells. Constituted of three isoforms, BTN3A
molecules are expressed by the majority of human immune
cells, including γδ-TCR T cells (142). Phosphoantigens bind
the intracellular domain B30.2 of BTN3A, which induces
conformational changes to the receptor and increases binding
force of Vγ9Vδ2 TCR to BTN3A (129, 143, 144). Therefore,
Vγ9Vδ2 T cells are able to recognize altered metabolites present
in infected or cancer cells.
Vγ 9Vδ2 T cells in tumor immunity
Once activated, Vγ9Vδ2 T cells acquire similar effector functions
as conventional αβ-TCR T cells: they directly kill tumor
cells upon engagement of death receptors (e.g., FAS, TRAIL,
NKG2D) or by secreting granzymes and perforins (24). In
addition, Vγ9Vδ2 T cells produce various pro-inflammatory
cytokines such as TNFα or IFNγ, and can modulate the
immune response. For example, Vδ9Vδ2 T cells can license
and accelerate DC maturation (145, 146) and provide help to
B cells (147).
Human γδ-TCR T cells can be expanded in vitro to clinically
relevant numbers, are able to migrate to and kill tumors, and are
amenable to genetic engineering (68–70, 148, 149). Both HLA
class I- and class II-restricted αβ-TCRs have been successfully
introduced into Vγ9Vδ2 T cells and recognized the cognate
peptide when co-transduced with CD4 or CD8 co-receptors (69,
70). TCRmispairing between α-/β-chains and γ-/δ-chains cannot
occur. Thus, γδ-TCR T cells are optimal recipients for transgenic
αβ-TCRs. αβ-TCR-transgenic γδ-TCR T cells express both αβ-
and γδ-TCRs andmediate tumor cytotoxicity through both TCRs
(69). Vγ9Vδ2 T cells were also engineered to transiently express
a TCR or a CAR and exerted both endogenous and engineered
properties (68).
One unique feature of Vγ9Vδ2 T cells is their capacity
to differentiate into professional APCs upon IPP stimulation.
Vγ9Vδ2 T cells can phagocytose cells and crosspresent antigens,
leading to the proliferation of both CD4+ and CD8+ T cells
(25, 26). This interesting feature is maintained in genetically
engineered Vγ9Vδ2 T cells. For example, GD2-CAR-transduced
Vγ9Vδ2 T cells killed GD2+ neuroblastoma, while retaining
their ability to endocytose long peptides derived from the
melanoma antigen MART-1 and inducing the proliferation
of autologous T cells transduced with a MART-1-specific
TCR (27).
Non-Vδ2 γδ-TCR T Cells
General background
Non-Vδ2 γδ-TCR T cells consist of Vδ1 and Vδ3 γδ-TCR T
cells, and are mostly tissue-resident T cells present in barrier
epithelium, though some of these cells are also circulating in
blood (127). Between these two subsets, Vδ1 are the most
abundant. From the original diverse repertoire present in
neonates, only few Vδ1 γδ-TCR T cell clones will expand and
ultimately dominate the adult Vδ1 repertoire (150). Even though
the antigens recognized by Vδ1 γδ-TCR T cells are mostly
unknown, they were shown to recognize ligands presented by
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CD1a, CD1c, CD1d, and MR1 molecules as well as various
stress-induced ligands (133, 151, 152).
CD1-Restricted Vδ1 γ δ-TCR T cells
CD1 molecules were among the first ligands identified for γδ-
TCR T cells (153), but only few CD1-restricted lipids recognized
by Vδ1 γδ-TCR T cells have been identified so far. Exogenous
antigens comprise pollen-derived phospholipids and bacterial
lipids, while known self-lipids consist of glycolipid sulfatides,
which are present in tissues where Vδ1 γδ-TCR T cells reside
(154–157). γδ-TCR T cells have been reported to be involved
in tissue repair and homeostasis (158, 159), and predominate
among γδ-TCR T cells that infiltrate various tumors (see below).
However, the presence of CD1-resticted γδ-TCR T cells in
tumors, and their involvement in tumor immunity, have not been
investigated yet.
Crystal structure of CD1d-Vδ1 binding reveals a distinct TCR
recognition: CD1d recognition by Vδ1 γδ-TCR T cells is solely
mediated by the germline-encoded CDR1 loop, independently
of the bound antigen. The antigen is in contact with the CDR3
region, which determines the antigen specificity (156, 160).
Similarly, CD1c recognition was also shown to be dictated solely
by Vδ1. Bound antigens modulate TCR recognition: some self-
lipids were shown to permit TCR binding, while other self-lipids
blocked it (154).
MR1-Restricted Vδ1 γ δ-TCR T cells
γδ-TCR T cells recognizing antigens presented by MR1 have
only been recently identified (152). This novel γδ-TCR T cell
subset is rare with a frequency between <0.001 and 0.1% of
total CD3+ T cells, or <0.1–5% of γδ-TCR T cells in blood of
healthy donors, but has also been found in TILs of a Merkel cell
carcinoma patient. MR1-restricted γδ-TCR T cells preferentially
expressed Vδ1 (72% of the 76 TCRs analyzed). Structural studies
revealed that TCR recognition occurred by binding to the MR1
α3 domain situated underneath the antigen-binding site and
independently of the bound antigen (152) suggesting inherent
autoreactivity of these cells.
Vδ1 γ δ-TCR T cells in tumor immunity
Consistent with their preferential localization in epithelial tissues,
Vδ1 γδ-TCR T cells are the predominant γδ-TCR T cell
population in the majority of solid tumors (28, 161–163). Vδ1
γδ-TCR T cell infiltration correlated with favorable prognosis
in several cancer types, such as triple negative breast cancer
(TNBC) or CLL (162, 164). Upon in vitro expansion, Vδ1 γδ-
TCR T cells isolated from PBMCs of cancer patients displayed
strong IFNγ secretion and cytotoxic responses against several
autologous tumors including melanoma (165), TNBC (162),
colon cancer (166), AML (71), CLL (164, 167), diffuse large
B cell lymphoma (168), and multiple myeloma (169). In vitro
expanded Vδ1 γδ-TCR T cells were able to kill autologous
CLL in vitro and spare healthy B cells isolated from the same
patient, thus showing their ability to distinguish transformed
cells from healthy cells (164). Moreover, these Vδ1 γδ-TCR
T cells restrained tumor growth and prolonged the survival
of immunodeficient mice engrafted with either human colon
cancer or AML (71, 166). In other tumors, such as breast
cancer (161, 170), colorectal cancer (163), melanoma (171), or
squamous cell carcinoma (172), Vδ1 γδ-TCR T cell infiltration
was associated with poor prognosis, as these cells displayed
an immunosuppressive phenotype promoting tumor growth
(170, 171). Vδ1 γδ-TCR T cells were shown to differentiate
into Th17-like T cells, producing elevated level of IL-17, and
other immunosuppressive factors, such as IL-10, IL-18, and
adenosine (161, 170). Cancer cells were directly responsible for
the skewing of Vδ1 γδ-TCR T cells toward Th17 regulatory
profile. Breast cancer, for example, secretes exosomes containing
the IncRNA SNHG16, a long non-coding RNA inducing the
expression of SMAD5, and therefore TGF-β1, in Vδ1 γδ-TCR T
cells (161). In colorectal cancer patients, cancer stem cells directly
promoted IL-17 production by Vδ1 γδ-TCR T cells by secreting
immunomodulatory molecules. By multiplex analyses on 50
different cytokines, the authors identified IL-18 and VEGF as the
two most promising candidates responsible for the skewing of
Vδ1 γδ-TCRT cells toward IL-17-producing immunosuppressive
cells (163).
So far, no clinical trials have investigated the safety and
efficacy of Vδ1 γδ-TCR T cells as anti-tumor therapy (Table 3).
However, several groups established GMP-compatible protocols
to expand and genetically engineer Vδ1 γδ-TCR T cells in
vitro with the goal to translate this approach to the clinic
(27, 28, 71, 72). Vδ1 γδ-TCR T cells can be expanded from
healthy donor or patient PBMCs using a cocktail of different
cytokines and anti-CD3 antibody stimulation. Over 3 weeks of
culture, cells expanded more than 3-log fold and differentiated
into cytotoxic Th1-like T cells, capable of controlling tumor
growth in xenograft mouse models (28, 71). Moreover, Vδ1
γδ-TCR T cells expanded from PBMCs could be transduced
with an anti-GD2 CAR and killed GD2-positive neuroblastoma
cells lines that were not naturally recognized by Vδ1 γδ-TCR T
cells (27).
γδ-TCR T Cells in Clinical Trials
Published and ongoing clinical trials investigating the safety
and antitumor function of γδ-TCR T cells have recently
been reviewed (173). Overall, the results of published trials
outside the setting of allogeneic HCT have been disappointing,
demonstrating safety but no efficacy. A major limitation lies
in the lack of understanding of γδ-TCR diversity and their
potential target antigens (Table 3). Some of the current and
future clinical trials are trying to address these issues. We
will focus our discussion on efforts in developing allogeneic
γδ-TCR T cell therapies, with the overall goal to move
their application to third-party banked off-the-shelf therapies.
We identified five registered clinical trials, but more are
expected to emerge. Three trials explore the safety of allogeneic
ex vivo expanded adoptively transferred γδ-TCR T cells in
hematologic malignancies. In one trial, γδ-TCR T cells are
expanded from the haploidentical stem cell donor and infused
to the patient post-transplant in combination with post-
transplant cyclophosphamide treatment (NCT03533816, Incysus
Therapeutics). Safety and effects on post-transplant GVHD are
investigated. Another trial assesses the adoptive transfer of ex vivo
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expanded γδ-TCR T cells derived from related haploidentical
or HLA-matched donors in patients with relapsed/refractory
AML after lymphodepleting chemotherapy (NCT03790072, TC
Biopharm). Safety and efficacy are analyzed. Future prospects
are to move to allogeneic third-party banked γδ-TCR T cell
products, and to include genetic engineering with CARs. A
third active trial is also investigating ex vivo expanded γδ-
TCR T cells from allogeneic related donors in patients with
relapsed/refractory AML (NCT04008381, Wuhan Hospital). For
solid tumors, a randomized clinical trial investigates safety and
efficacy of tumor reducing surgery alone or in combination with
adoptive transfer of ex vivo expanded γδ-TCR T cells in patients
with locally advanced pancreatic cancer. The source of the γδ-
TCR T cells is not entirely clear (NCT03180437, Fuda Cancer
Hospital). Finally, haploidentical NKG2DL-CAR engineered γδ-
TCRT cells for a variety of relapsed or refractory solid tumors will
be investigated in a phase I dose escalation trial (NCT04107142,
Cytomed Therapeutics).
γδ-TCR T Cells as Platform for ACT
γδ-TCR T cell expansion protocols allow the incorporation
of genetic engineering to redirect γδ-TCR T cells to tumor-
associated antigens recognized by CARs or αβ-TCRs (28, 68, 71,
72). Preclinical data suggest that γδ-TCR T cells are particularly
suitable for αβ-TCR-based engineering, as the risk of TCR
mispairing is inexistent. Both TCRs remain well-expressed, and
the redirected T cells can exert anti-tumor functions through
both TCRs. As γδ-TCR T cells are not HLA restricted (137), there
is theoretically no risk of causing GVHD in the recipients, but
formal demonstration in a clinical trial with third-party donor
derived γδ-TCR T cells is currently lacking. γδ-TCR T cells
meet many features required for universal donor T cell therapies
(Table 1), and the interest in the field of exploiting this cell type
is high.
UNIVERSAL TCR
TCRs derived from both αβ- and γδ-TCR repertoires that
allow the targeting of a broad range of tumors in an HLA
independent manner have been identified. These TCRs can
be considered “universal,” as they redirect immune cells to
broadly shared tumor-specific antigens. TCRs recognizing targets
derived from altered cell metabolism are of particular interest,
as these TCRs reliably distinguish between cancer and healthy
cells. Three examples from the literature include Vγ9Vδ2 TCRs
(174, 175), mLPA-specific CD1c-restricted αβ-TCRs (64), and an
MR1-restricted αβ-TCR with unknown specificity (108). These
TCRs have been successfully introduced into polyclonal αβ-
TCR T cells and were able to redirect the engineered cells to a
variety of cancers in an HLA-independent manner in preclinical
studies. Autologous Vγ9Vδ2-TCR engineered αβ-TCR T cells
are currently under phase I clinical evaluation in patients
with hematologic malignancies (NTR6541, UMC Utrecht). More
TCRs with similar features are likely to be identified in the
future. TCRs targeting cancer-specific ligands in the context
of non-polymorphic molecules are likely to become interesting
candidates for engineered ACTs.
CONCLUSIONS AND FUTURE OUTLOOK
VSTs and unconventional T cells possess several features
that would enable their universal use without the need of
genome editing to avoid unacceptable alloreactivity. Among
these different T cell subsets, γδ-TCRT cells, especially Vγ9Vδ2 T
cells, and iNKT cells show the highest universal potential
(Table 1). However, whether or not host-mediated rejection
of the infused cells will affect their engraftment and long-
term persistence remains to be addressed in the upcoming
clinical trials. The only data available to date on persistence,
safety, and efficacy come from third-party banked VSTs where,
despite excellent clinical activity, persistence seems to be
reduced compared to other trials that used HLA-matched
products. Characterized by a memory-like status, VSTs and
unconventional T cells respond rapidly to antigen exposure,
leading to strong cytolytic activity, and cytokine production
(19). Several of these T cell types have successfully been
redirected to tumors by genetic engineering with a CAR or
a TCR and mostly retain their intrinsic characteristics. For
example, CAR+ VSTs maintain their anti-viral responses (48,
49), γδ-TCR T cells express both endogenous and introduced
αβ-TCR (69), and CAR+ iNKT cells continue to respond to
α-GalCer (57, 59, 176). The retention of these cell-specific
features can also promote their in vivo re-expansion after
ACT through re-exposure to their natural cognate antigen
(49). Another advantage is the relatively restricted pattern of
target antigens recognized by their endogenous TCRs. CD1-
restricted and γδ-TCR T cells, for example, recognize ligands
derived from altered tumor metabolism, and thus spare the
corresponding healthy cells (36, 43). Despite still limited
understanding of the biology of certain unconventional T cell
subsets, the developing clinical translational pipelines outlined
in this review demonstrate that the future potential for some
of these experimental therapies as off-the-shelf products is
high (Table 3). We expect that some of these cell types or
universal receptors will become important players in the field
cancer immunotherapy.
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